Association of immune checkpoint inhibitors (ICI) and venous thromboembolism (VTE) in non–small-cell lung cancer (NSCLC): A single healthcare system experience.

Authors

Sowbharnika Arivazhagan, Baton Rouge General Medical Center
Aneesha Ananthula, LSU Health Sciences Center - New Orleans
Julijana Zoran Conic, LSU Health Sciences Center - New OrleansFollow
Conner Daniel Hartupee, LSU Health Sciences Center - New OrleansFollow
Daniel Richard Edmund, LSU Health Sciences Center - New OrleansFollow
Andrew W. Mercante, LSU Health Sciences Center - New OrleansFollow
Taylor J. Marks, LSU Health Sciences Center - New OrleansFollow
Andrew G. Chapple, LSU Health Sciences Center - New OrleansFollow
Brian C. Boulmay, LSU Health Sciences Center - New OrleansFollow

Document Type

Conference Proceeding

Publication Date

5-31-2023

Publication Title

Journal of Clinical Oncology

Abstract

2023 American Society of Clinical Oncology Annual Meeting, ASCO, June 2 - 6, 2023, Chicago, IL

First Page

e14680

Volume

41

Publisher

American Society of Clinical Oncology

Comments

Abstract Number: e14680

ISBN

0732183X

Recommended Citation

Arivazhagan, Sowbharnika; Ananthula, Aneesha; Conic, Julijana Zoran; Hartupee, Conner Daniel; Edmund, Daniel Richard; Mercante, Andrew W.; Marks, Taylor J.; Chapple, Andrew G.; and Boulmay, Brian C., "Association of immune checkpoint inhibitors (ICI) and venous thromboembolism (VTE) in non–small-cell lung cancer (NSCLC): A single healthcare system experience." (2023). School of Medicine Faculty Publications. 2371.
https://digitalscholar.lsuhsc.edu/som_facpubs/2371
10.1200/JCO.2023.41.16_suppl.e14680